Tysabri (Natalizumab)-induced POU2AF1/Spi-B upregulation: STUDY

Image Source: TREATMERIGHTMS

Re-evaluating the Incidence of Tysabri (Natalizumab)-Associated Progressive Multifocal Leukoencephalopathy: STUDY

Image Source: RYO1M

MS drug influences John Cunningham virus antibody levels

Image Source: UNI-MUENSTER

The multiple sclerosis treatment Tysabri (natalizumab) may be associated with increased levels of John Cunningham virus antibodies, indicating increased risk for fatal brain disease caused by the infection, according to recent data.

Monitoring the John Cunningham virus throughout Tysabri (natalizumab) treatment in MS patients: STUDY

HISTOLOGY: NERVOUS: BRAIN: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, PML; MULTINUCLEATED ASTROCYTE
Image Source: PEIRDIGITALLIBRARY

Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy (PML): Risks and Detection: VIDEO

Fred Lublin, MD, explains that prior to the use of Tysabri (natalizumab), progressive multifocal leukoencephalopathy (PML) had never been observed in patients with multiple sclerosis (MS). Providing accurate figures about the risk of PML to patients who may be or are being treated with natalizumab iscritically important in makingthe best treatment choices. PML is not as severe and lethal in the setting of MS as in other diseases, such as HIV. Still, he adds,PML often leaves individuals left with some kind of disability, and the mortality rate in MS is about 20%.

Researchers Suggest Short Transition Period Between Tysabri (Natalizumab) and Gilenya (Fingolimod) Therapies to Control RRMS Disease Activity

An international team led by researchers at the University Hospital Basel in Switzerland revealed that a short period of 8 to 12 weeks is the optimal timing to be considered when patients with relapsing-remitting multiple sclerosis (RRMS) are switched from natalizumab to fingolimod therapy. The study was recently published in the journal Neurology and is entitled “Switching from natalizumab to fingolimod, A randomized, placebo-controlled study in RRMS.”

Markers of JC virus infection in patients with multiple sclerosis under Tysabri (natalizumab) therapy: STUDY

Immunological biomarkers identifying Tysabri (natalizumab)-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy

Progressive Multifocal leukoencephalopathy (PML)

Tecfidera-Related Progressive Multifocal Leukoencephalopathy (PML) Reported

Los Angeles, CA: The first known incidence of PML, or progressive multifocal leukoencephalopathy, in a patient taking Tecfidera, has been confirmed by Biogen Idec, the maker of the new treatment for multiple sclerosis (MS).

The power of social networking in medicine

Figure 1: Example of a PatientsLikeMe profile

Findings on Monoclonal Antibodies Detailed by Investigators at University Hospital - Tysabri (Natalizumab) treatment alters the expression of T-cell trafficking...

According to news reporting originating from Lausanne, Switzerland, by NewsRx correspondents, research stated, "To determine the long-term effect of natalizunnab (NTZ) treatment on the expression of integrins and chenmokine receptors involved in the migration of T cells towards the central nervous system (CNS). We drew the blood of 23 patients just before starting NTZ therapy and every 12 months thereafter, for up to 48 months of treatment."

IMPORTANT NEW STUDY WITH GREAT NEWS: Tysabri/Natalizumab Continued Past 24 Months Safely in MS